Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03021551 · ClinicalTrials.gov registry record

Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients

A clinical trial of Surgery and Morbid Obesity, sponsored by Masimo Corporation.

Completed
Registry status
80
Enrollment target
1
Study location

NCT03021551 is a study of Surgery and Morbid Obesity that has completed, run by Masimo Corporation. The registered enrollment target is 80 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03021551, a study of Surgery and Morbid Obesity, has completed, sponsored by Masimo Corporation.

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to partial pressure of oxygen (PaO2) values of 100 mmHg and below and an ORi of 1.00 corresponds to PaO2 values of 200 mmHg and above. This is clinical study designed to evaluate the clinical utility of the Oxygen Reserve Index (ORI) as an early warning for arterial hemoglobin desaturation during the induction of general anesthesia and tracheal intubation in obese patients undergoing elective surgical procedures.

Conditions Studied

Interventions

  • DEVICE Rainbow sensor

Study Locations (1)

California

  • UC Davis Health - Sacramento

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2016-09-15
Est. Completion 2018-07-20

Sponsor

Masimo Corporation

96 total trials

What the Registry Record Tells You About NCT03021551

The ClinicalTrials.gov registry entry for NCT03021551 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is Masimo Corporation, which has 96 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Surgery appearing as the primary indexed condition, and to 1 intervention - of which Rainbow sensor is the first listed.

NCT03021551 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03021551 about?

NCT03021551 is a clinical study titled "Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients". The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to partial pressure of oxygen (PaO2) values of 100 mmHg and below and an O...

What is the current status of trial NCT03021551?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2016-09-15. Estimated completion is 2018-07-20.

What conditions does trial NCT03021551 study?

This clinical trial studies the following conditions: Surgery, Morbid Obesity.

What interventions are being tested in trial NCT03021551?

The interventions under investigation include: Rainbow sensor (DEVICE).

Who is sponsoring clinical trial NCT03021551?

This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03021551 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.